Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » PCR » Bio-Me Awarded $2.2M to Develop Microbiome Biomarker Test for Cancer Immunotherapy

Bio-Me Awarded $2.2M to Develop Microbiome Biomarker Test for Cancer Immunotherapy

Apr 22, 2020
|
staff reporter

NEW YORK ─ Bio-Me said Wednesday it has received €2 million ($2.2 million) in grants and public funding from the Norwegian Research Council to develop a companion diagnostic test for immune checkpoint inhibitor cancer treatments.

Its development involves key Norwegian and international partners and a collaboration between leading clinical experts and academic researchers in the field, Bio-Me said. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Plans Out

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

CovidNudge Numbers

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

Science Papers Propose Group to Discuss Genome-Editing Tools, Markers of Diabetes Drug Response, More

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

Not Counting These

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Sep
24
Featured Webinar

New Insights Underscore the Need to Identify NTRK Fusions in Childhood Tumors

Sponsored by
ArcherDX

NTRK fusions are oncogenic drivers in a variety of tumors.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

What's Popular?

In PCR

  1. FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

    Premium

  2. Qiagen Acquires Remaining Stake in NeuMoDx Molecular for $248M

  3. Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

  4. FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

  5. DiaSorin Receives CE Mark to Use Saliva Samples With COVID-19 Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.